AUM Biosciences - Crunchbase Company Profile & Funding

Q: Who invested in AUM Biosciences?

AUM Biosciences has 3 investors including Everlife And SPRIM.

Q: When was the last funding round for AUM Biosciences?

AUM Biosciences closed its last funding round on obfuscated from a Series A round.

Q: How much funding has AUM Biosciences raised to date?

AUM Biosciences has raised obfuscated.

Overview

AUM Biosciences

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Events

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About AUM Biosciences

CB Rank

54146

AUM Biosciences is committed to addressing the unmet medical needs by developing innovative and affordable oncology therapeutics for Asia.

Founded

obfuscation

Private

Series A

Singapore, Central Region, Singapore

11-50

www.aumbiosciences.com/

Biotechnology

Oncology

Funding Rounds

Series A

OBF

obfuscation

Seed

OBF

obfuscation

Key People

John Patava: Chief Operating Officer
Thyagesh Baba: Member, Advisor to CEO

Details

Legal Name

AUM Biosciences Pte. Ltd.

Also Known As

AUM

Operating Status

Active

Company Type

For Profit

Founders

Vishal Doshi

About the Company

AUM Biosciences is an oncology-focused biotechnology company that aims to accelerate the development of innovative, affordable medicines for patients in Asia and around the world. AUM Biosciences focuses on early-stage development of innovative medicines for the treatment of Asian-prevalent cancers.

Phone Number

+65 6808 6034

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

AUM001

AUM001 is an oncology therapeutic agent designed to be used in combination with other cancer treatments to address solid tumors and colorectal cancer.

NOV1601 (CHC2014)

NOV1601 is a small-molecule pan-TRK inhibitor developed for treating adult patients with solid organ malignancies by targeting TRK family proteins.

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - AUM Biosciences	3	obfuscated obfuscation	Everlife, SPRIM	Series A
obfuscated obfuscation	Series A - AUM Biosciences	3	obfuscated obfuscation	Everlife, SPRIM	Series A
obfuscated obfuscation	Series A - AUM Biosciences	3	obfuscated obfuscation	Everlife, SPRIM	Series A
obfuscated obfuscation	Series A - AUM Biosciences	3	obfuscated obfuscation	Everlife, SPRIM	Series A
obfuscated obfuscation	Series A - AUM Biosciences	3	obfuscated obfuscation	Everlife, SPRIM	Series A

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - AUM Biosciences	3	obfuscated obfuscation	Everlife, SPRIM	Series A
obfuscated obfuscation	Series A - AUM Biosciences	3	obfuscated obfuscation	Everlife, SPRIM	Series A
obfuscated obfuscation	Series A - AUM Biosciences	3	obfuscated obfuscation	Everlife, SPRIM	Series A
obfuscated obfuscation	Series A - AUM Biosciences	3	obfuscated obfuscation	Everlife, SPRIM	Series A
obfuscated obfuscation	Series A - AUM Biosciences	3	obfuscated obfuscation	Everlife, SPRIM	Series A

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Everlife	Yes	Series A - AUM Biosciences	Arjun Oberoi
Everlife	Yes	Series A - AUM Biosciences	Arjun Oberoi
Everlife	Yes	Series A - AUM Biosciences	Arjun Oberoi
Everlife	Yes	Series A - AUM Biosciences	Arjun Oberoi
Everlife	Yes	Series A - AUM Biosciences	Arjun Oberoi

Market Intelligence

People

View Profiles & Contacts

Headcount

11-50

Employee Profiles

Contacts

Employee Profiles

John Patava Chief Operating Officer
Thyagesh Baba Member, Advisor to CEO
Scott Jordan Head of Corporate Development - Tyrosine Kinase Inhibitors - Phase 2
Ross Horsburgh Non-Executive Director